Currently the countries participating in the RESILIENCE project are: Spain with 13 associated centers, France, Portugal, Germany, Denmark and the Netherlands. Click here if you would like to know more!
The trial is currently intended to study only lymphoma. We hope that in the future, patients with other types of cancer may benefit.
Patients eligible to participate in the trial must be 18 years of age or older. In fact, being over the age of 65 is considered a risk factor for developing cardiotoxicity.
The intervention has been studied in other clinical trials, such as the CONDI-2 study, which shows that the therapy is safe, since no serious adverse effect related to it was reported in more than 5,000 patients.
Your doctor will ensure that you meet the study inclusion criteria. Among them are that it is your first treatment with anthracyclines or that there is no contraindication to be able to do the MRIs.
In order to determine if the treatment is working in patients with lymphoma, we still have a long way to go. We rely on the evidence of its benefits in the animal model and in other pathologies such as myocardial infarction. We continue working to advance in the benefit of our patients.